Form 4: REGENXBIO Director Jennifer Zachary Reports Stock and Option Transactions

Director Jennifer Zachary reports acquisition of common stock and stock options in REGENXBIO Inc.

Summary

• On May 31, 2024, Jennifer Zachary, a director of REGENXBIO Inc., acquired 4,790 shares of common stock and disposed of 14,296 shares.
• These shares were acquired through a time-based restricted stock unit award (RSU), which will fully vest on May 1, 2025, contingent upon continuous service.
• Zachary also acquired 24,454 stock options with an exercise price of $14.35, vesting in 12 equal monthly installments starting May 31, 2024, also subject to continuous service.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of insider transactions. The acquisition of shares and options is mildly positive, while the disposal of shares is mildly negative. Overall, it doesn't strongly indicate a positive or negative outlook.

Positives

• The acquisition of stock options and restricted stock units by a director signals confidence in the company's future performance.

Negatives

• The disposal of 14,296 shares of common stock by a director could be interpreted negatively by investors.

Risks

• The vesting of the RSU and stock options is contingent upon the director's continuous service, creating a potential risk if the director leaves the company.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedules of the RSU and stock options indicate a multi-year commitment from the director.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for insights into management's confidence in the company's prospects.

Comparison to Industry Standards

• Stock option grants and RSU awards are standard compensation practices for directors and executives in the biotechnology industry.
• Companies like Amgen, Gilead Sciences, and Biogen also use similar equity-based compensation to align the interests of management with those of shareholders.
• The vesting schedules and exercise prices are generally in line with industry norms for companies of REGENXBIO's size and stage of development.

Stakeholder Impact

• The transactions could have a minor impact on shareholder sentiment, depending on how investors interpret the director's actions.

Key Dates